Lutetium Lu 177 Dotatate has 3 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Octreotide Acetate, Octreotide, Somatostatin. Patients taking Lutetium Lu 177 Dotatate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 3
- Contraindicated
- 1
- Major
- 2
Contraindicated (1)
- Lutetium Lu 177 Dotatate + Octreotide Acetate— Octreotide competitively binds somatostatin receptors and may interfere with lutetium Lu 177 dotatate efficacy. Disconti…
Major (2)
- Lutetium Lu 177 Dotatate + Octreotide— Short-acting octreotide competitively binds to somatostatin receptors and may interfere with LUTATHERA efficacy. Discont…
- Lutetium Lu 177 Dotatate + Somatostatin— Somatostatin analogs competitively bind to somatostatin receptors and may interfere with LUTATHERA efficacy. Discontinue…